Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Model for End-stage Liver Disease (MELD)

Kiran Bambha, MD, MS
Patrick S Kamath, MD
Section Editor
Bruce A Runyon, MD
Deputy Editor
Kristen M Robson, MD, MBA, FACG


Prognostic models are useful for estimating disease severity and survival, and can serve as helpful medical decision-making tools with respect to guiding patient care. These models are developed using statistical methodologies that involve determining the effects of variables of interest (eg, demographic data, clinical data, and laboratory values) on specific outcomes such as death.

Several prognostic models are currently used in healthcare settings. Some focus on generalized health status such as the Acute Physiology and Chronic Health Evaluation System (APACHE III) [1], while others are disease specific. Examples of the latter in the field of hepatology include models for predicting survival in patients with primary biliary cholangitis, primary sclerosing cholangitis, and alcoholic liver disease [2-5]. Two models that are used commonly in the care of patients with cirrhosis are the Child-Turcotte-Pugh score and the Model for End-stage Liver Disease (MELD) score [6-10].

This topic will review the development, use, impact, refinements, and limitations of the MELD score, particularly with regard to its use in allocating organs for liver transplantation. Other issues related to the selection of patients for liver transplantation are discussed separately. (See "Liver transplantation in adults: Patient selection and pretransplantation evaluation".)


The Model for End-stage Liver Disease (MELD) is a prospectively developed and validated chronic liver disease severity scoring system that uses a patient's laboratory values for serum bilirubin, serum creatinine, and the international normalized ratio (INR) for prothrombin time to predict three-month survival (calculator 1 and calculator 2). In patients with cirrhosis, an increasing MELD score is associated with increasing severity of hepatic dysfunction and increased three-month mortality risk (figure 1) [11]. Given its accuracy in predicting short-term survival among patients with cirrhosis, MELD was adopted by the United Network for Organ Sharing (UNOS) in 2002 for prioritization of patients awaiting liver transplantation in the United States. (See 'Adoption of MELD for organ allocation' below and "Liver transplantation in adults: Patient selection and pretransplantation evaluation", section on 'Cirrhosis'.)

Development of the MELD score — MELD was originally developed to predict three-month mortality following transjugular intrahepatic portosystemic shunt (TIPS) placement and was derived using data from a population of 231 patients with cirrhosis who underwent elective TIPS placement. The model was subsequently validated in an independent cohort of patients from the Netherlands undergoing TIPS placement [8]. The original model included serum bilirubin, serum creatinine, INR, and etiology of the liver disease (cholestatic or alcoholic versus other etiologies).

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Sep 29, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. www.openclinical.org/aisp_apache.html (Accessed on March 17, 2011).
  2. Dickson ER, Grambsch PM, Fleming TR, et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989; 10:1.
  3. Grambsch PM, Dickson ER, Kaplan M, et al. Extramural cross-validation of the Mayo primary biliary cirrhosis survival model establishes its generalizability. Hepatology 1989; 10:846.
  4. Kim WR, Therneau TM, Wiesner RH, et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin Proc 2000; 75:688.
  5. Maddrey WC, Boitnott JK, Bedine MS, et al. Corticosteroid therapy of alcoholic hepatitis. Gastroenterology 1978; 75:193.
  6. Child III, CG, Turcotte, JG. Surgery and portal hypertension. In: The Liver and Portal Hypertension, Child III CG (Ed), Saunders, Philadelphia 1964. p.50.
  7. Pugh RN, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973; 60:646.
  8. Malinchoc M, Kamath PS, Gordon FD, et al. A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts. Hepatology 2000; 31:864.
  9. Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end-stage liver disease. Hepatology 2001; 33:464.
  10. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol 2006; 44:217.
  11. Freeman RB Jr, Wiesner RH, Harper A, et al. The new liver allocation system: moving toward evidence-based transplantation policy. Liver Transpl 2002; 8:851.
  12. Wiesner RH, McDiarmid SV, Kamath PS, et al. MELD and PELD: application of survival models to liver allocation. Liver Transpl 2001; 7:567.
  13. Wiesner R, Edwards E, Freeman R, et al. Model for end-stage liver disease (MELD) and allocation of donor livers. Gastroenterology 2003; 124:91.
  14. Said A, Williams J, Holden J, et al. Model for end stage liver disease score predicts mortality across a broad spectrum of liver disease. J Hepatol 2004; 40:897.
  15. https://optn.transplant.hrsa.gov/search-results?q=MELD (Accessed on January 24, 2014).
  16. https://optn.transplant.hrsa.gov/news/meld-serum-sodium-policy-changes/.
  17. Leise MD, Kim WR, Kremers WK, et al. A revised model for end-stage liver disease optimizes prediction of mortality among patients awaiting liver transplantation. Gastroenterology 2011; 140:1952.
  18. Kim WR, Biggins SW, Kremers WK, et al. Hyponatremia and mortality among patients on the liver-transplant waiting list. N Engl J Med 2008; 359:1018.
  19. Heuman DM, Abou-Assi SG, Habib A, et al. Persistent ascites and low serum sodium identify patients with cirrhosis and low MELD scores who are at high risk for early death. Hepatology 2004; 40:802.
  20. Luca A, Angermayr B, Bertolini G, et al. An integrated MELD model including serum sodium and age improves the prediction of early mortality in patients with cirrhosis. Liver Transpl 2007; 13:1174.
  21. Londoño MC, Cárdenas A, Guevara M, et al. MELD score and serum sodium in the prediction of survival of patients with cirrhosis awaiting liver transplantation. Gut 2007; 56:1283.
  22. Biggins SW, Kim WR, Terrault NA, et al. Evidence-based incorporation of serum sodium concentration into MELD. Gastroenterology 2006; 130:1652.
  23. Ruf AE, Kremers WK, Chavez LL, et al. Addition of serum sodium into the MELD score predicts waiting list mortality better than MELD alone. Liver Transpl 2005; 11:336.
  24. Guy J, Somsouk M, Shiboski S, et al. New model for end stage liver disease improves prognostic capability after transjugular intrahepatic portosystemic shunt. Clin Gastroenterol Hepatol 2009; 7:1236.
  25. Biselli M, Gitto S, Gramenzi A, et al. Six score systems to evaluate candidates with advanced cirrhosis for orthotopic liver transplant: Which is the winner? Liver Transpl 2010; 16:964.
  26. Broadwater JR, Henderson MA, Bell JL, et al. Outpatient percutaneous central venous access in cancer patients. Am J Surg 1990; 160:676.
  27. Lim YS, Larson TS, Benson JT, et al. Serum sodium, renal function, and survival of patients with end-stage liver disease. J Hepatol 2010; 52:523.
  28. http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease/post-operative-mortality-risk-patients-cirrhosis (Accessed on January 21, 2014).
  29. Bambha K, Kim WR, Pedersen R, et al. Predictors of early re-bleeding and mortality after acute variceal haemorrhage in patients with cirrhosis. Gut 2008; 57:814.
  30. Reverter E, Tandon P, Augustin S, et al. A MELD-based model to determine risk of mortality among patients with acute variceal bleeding. Gastroenterology 2014; 146:412.
  31. Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the Meld system: a prospective study from a single European center. Am J Transplant 2006; 6:1572.
  32. Asrani SK, Kim WR. Model for end-stage liver disease: end of the first decade. Clin Liver Dis 2011; 15:685.
  33. Kremers WK, van IJperen M, Kim WR, et al. MELD score as a predictor of pretransplant and posttransplant survival in OPTN/UNOS status 1 patients. Hepatology 2004; 39:764.
  34. Schmidt LE, Larsen FS. MELD score as a predictor of liver failure and death in patients with acetaminophen-induced liver injury. Hepatology 2007; 45:789.
  35. Sharma P, Schaubel DE, Gong Q, et al. End-stage liver disease candidates at the highest model for end-stage liver disease scores have higher wait-list mortality than status-1A candidates. Hepatology 2012; 55:192.
  36. Freeman RB Jr, Edwards EB. Liver transplant waiting time does not correlate with waiting list mortality: implications for liver allocation policy. Liver Transpl 2000; 6:543.
  37. Institute of Medicine. Analysis of waiting times. In: Committee on Organ Transplantation. Assessing current policies and the potential impact of the DHHS final rule, National Academy Press, Washington DC 1999. p.57.
  38. Organ Procurement and Transplantation Network--HRSA. Final rule with comment period. Fed Regist 1998; 63:16296.
  39. Gleisner AL, Muñoz A, Brandao A, et al. Survival benefit of liver transplantation and the effect of underlying liver disease. Surgery 2010; 147:392.
  40. Schaubel DE, Guidinger MK, Biggins SW, et al. Survival benefit-based deceased-donor liver allocation. Am J Transplant 2009; 9:970.
  41. Merion RM, Schaubel DE, Dykstra DM, et al. The survival benefit of liver transplantation. Am J Transplant 2005; 5:307.
  42. www.unos.org (Accessed on June 12, 2006).
  43. Biggins SW, Bambha K. MELD-based liver allocation: who is underserved? Semin Liver Dis 2006; 26:211.
  44. Organ Procurement and Transplantation Network http://optn.transplant.hrsa.gov/policiesAndBylaws/policies.asp (Accessed on February 08, 2014).
  45. Ioannou GN, Perkins JD, Carithers RL Jr. Liver transplantation for hepatocellular carcinoma: impact of the MELD allocation system and predictors of survival. Gastroenterology 2008; 134:1342.
  46. https://optn.transplant.hrsa.gov/news/revised-liver-policy-regarding-hcc-exception-scores/#schedule (Accessed on September 07, 2016).
  47. Freeman RB Jr, Gish RG, Harper A, et al. Model for end-stage liver disease (MELD) exception guidelines: results and recommendations from the MELD Exception Study Group and Conference (MESSAGE) for the approval of patients who need liver transplantation with diseases not considered by the standard MELD formula. Liver Transpl 2006; 12:S128.
  48. Goldberg DS, Fallon MB. Model for end-stage liver disease-based organ allocation: managing the exceptions to the rules. Clin Gastroenterol Hepatol 2013; 11:452.
  49. Freeman RB, Wiesner RH, Edwards E, et al. Results of the first year of the new liver allocation plan. Liver Transpl 2004; 10:7.
  50. Cejas NG, Villamil FG, Lendoire JC, et al. Improved waiting-list outcomes in Argentina after the adoption of a model for end-stage liver disease-based liver allocation policy. Liver Transpl 2013; 19:711.
  51. Moylan CA, Brady CW, Johnson JL, et al. Disparities in liver transplantation before and after introduction of the MELD score. JAMA 2008; 300:2371.
  52. Freeman RB Jr. Model for end-stage liver disease (MELD) for liver allocation: a 5-year score card. Hepatology 2008; 47:1052.
  53. Schaubel DE, Sima CS, Goodrich NP, et al. The survival benefit of deceased donor liver transplantation as a function of candidate disease severity and donor quality. Am J Transplant 2008; 8:419.
  54. Volk ML, Lok AS, Pelletier SJ, et al. Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology 2008; 135:1568.
  55. Shafer TJ, Wagner D, Chessare J, et al. US organ donation breakthrough collaborative increases organ donation. Crit Care Nurs Q 2008; 31:190.
  56. Cholongitas E, Marelli L, Kerry A, et al. Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant 2007; 7:685.
  57. Bambha KM, Biggins SW. Inequities of the Model for End-Stage Liver Disease: an examination of current components and future additions. Curr Opin Organ Transplant 2008; 13:227.
  58. Lai JC, Terrault NA, Vittinghoff E, Biggins SW. Height contributes to the gender difference in wait-list mortality under the MELD-based liver allocation system. Am J Transplant 2010; 10:2658.
  59. Alessandria C, Ozdogan O, Guevara M, et al. MELD score and clinical type predict prognosis in hepatorenal syndrome: relevance to liver transplantation. Hepatology 2005; 41:1282.
  60. Terra C, Guevara M, Torre A, et al. Renal failure in patients with cirrhosis and sepsis unrelated to spontaneous bacterial peritonitis: value of MELD score. Gastroenterology 2005; 129:1944.
  61. Taylor RM, Davern T, Munoz S, et al. Fulminant hepatitis A virus infection in the United States: Incidence, prognosis, and outcomes. Hepatology 2006; 44:1589.
  62. Inaba K, Barmparas G, Resnick S, et al. The Model for End-Stage Liver Disease score: an independent prognostic factor of mortality in injured cirrhotic patients. Arch Surg 2011; 146:1074.
  63. Chalasani N, Kahi C, Francois F, et al. Model for end-stage liver disease (MELD) for predicting mortality in patients with acute variceal bleeding. Hepatology 2002; 35:1282.
  64. Amitrano L, Guardascione MA, Bennato R, et al. MELD score and hepatocellular carcinoma identify patients at different risk of short-term mortality among cirrhotics bleeding from esophageal varices. J Hepatol 2005; 42:820.
  65. Kim MS, Kato TS, Farr M, et al. Hepatic dysfunction in ambulatory patients with heart failure: application of the MELD scoring system for outcome prediction. J Am Coll Cardiol 2013; 61:2253.
  66. Montgomery A, Ferral H, Vasan R, Postoak DW. MELD score as a predictor of early death in patients undergoing elective transjugular intrahepatic portosystemic shunt (TIPS) procedures. Cardiovasc Intervent Radiol 2005; 28:307.
  67. Ferral H, Vasan R, Speeg KV, et al. Evaluation of a model to predict poor survival in patients undergoing elective TIPS procedures. J Vasc Interv Radiol 2002; 13:1103.
  68. Ferral H, Gamboa P, Postoak DW, et al. Survival after elective transjugular intrahepatic portosystemic shunt creation: prediction with model for end-stage liver disease score. Radiology 2004; 231:231.
  69. http://www.mayoclinic.org/medical-professionals/model-end-stage-liver-disease/meld-score-90-day-mortality-rate-alcoholic-hepatitis (Accessed on January 21, 2014).
  70. Trotter JF, Brimhall B, Arjal R, Phillips C. Specific laboratory methodologies achieve higher model for endstage liver disease (MELD) scores for patients listed for liver transplantation. Liver Transpl 2004; 10:995.
  71. Tripodi A, Chantarangkul V, Primignani M, et al. The international normalized ratio calibrated for cirrhosis (INR(liver)) normalizes prothrombin time results for model for end-stage liver disease calculation. Hepatology 2007; 46:520.
  72. Bellest L, Eschwège V, Poupon R, et al. A modified international normalized ratio as an effective way of prothrombin time standardization in hepatology. Hepatology 2007; 46:528.
  73. Cholongitas E, Marelli L, Kerry A, et al. Different methods of creatinine measurement significantly affect MELD scores. Liver Transpl 2007; 13:523.
  74. Miller WG, Myers GL, Ashwood ER, et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005; 129:297.
  75. Sharma P, Schaubel DE, Sima CS, et al. Re-weighting the model for end-stage liver disease score components. Gastroenterology 2008; 135:1575.